Efficacy of dapsone administered alone or in combination with diazepam to inhibit status epilepticus in rats.
Animals
Anticonvulsants
/ pharmacology
Dapsone
/ pharmacology
Diazepam
/ pharmacology
Electroencephalography
Hippocampus
/ drug effects
Kainic Acid
/ adverse effects
Male
Neurons
/ drug effects
Neuroprotective Agents
/ pharmacology
Pyramidal Cells
/ drug effects
Rats
Rats, Wistar
Seizures
/ chemically induced
Status Epilepticus
/ chemically induced
Dapsone
Diazepam
Kainic acid
Rats
Status epilepticus
Journal
Brain research
ISSN: 1872-6240
Titre abrégé: Brain Res
Pays: Netherlands
ID NLM: 0045503
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
received:
07
09
2018
revised:
13
11
2018
accepted:
12
12
2018
pubmed:
21
12
2018
medline:
17
6
2020
entrez:
21
12
2018
Statut:
ppublish
Résumé
Status epilepticus (SE) is a serious medical condition, as it may trigger epileptogenesis. SE produces continuous generalized seizures resulting in irreversible brain damage. Therefore, the use of neuroprotective agents to prevent cell damage, may reduce the impact of SE. The use of diazepam (DZP), has shown limited neuroprotective effect in SE patients. According to previous reports, dapsone (DDS) is able to reduce both cell damage and seizures, when administered 30 min before the onset of seizures. This study is aimed to evaluate the ability of DDS, alone or in combination with DZP starting their administration once the SE is onset to evaluate the control of seizures in rats. Results showed a reduced convulsive electrical activity after 30 min, 1 and 2 h after SE induced by kainic acid (KA) administration, in the animals treated with DZP alone or in combination with DDS. At 24 h, we observed electrical activity similar to baseline in all groups receiving treatment. The animals treated with DDS and DZP alone or in combination showed an increase in the number of viable pyramidal cells but only the combination showed a lower number of damaged pyramidal neurons of hippocampal CA3. In conclusion, DDS plus DZP was able to control SE and to prevent SE-induced damage, when administered in combination with DZP. As DDS is already in use for patients with leprosy, that combination may be a safe, good option for human cases of SE.
Identifiants
pubmed: 30571982
pii: S0006-8993(18)30633-4
doi: 10.1016/j.brainres.2018.12.017
pii:
doi:
Substances chimiques
Anticonvulsants
0
Neuroprotective Agents
0
Dapsone
8W5C518302
Diazepam
Q3JTX2Q7TU
Kainic Acid
SIV03811UC
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-187Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.